July 24, 2023 07:21 AM EDTUpdated 09:18 AM
R&D

Ko­di­ak ends at­tempt at an Eylea ri­val as its bi­o­log­ic fails two of three PhI­II tri­als

Kyle LaHucik

Senior Reporter

Ko­di­ak Sci­ences’ at­tempt at mak­ing an Eylea ri­val for pa­tients with var­i­ous eye con­di­tions has come to an end.

The Cal­i­for­nia biotech is

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

FTC to sue ma­jor PBMs over in­sulin re­bates, claim­ing they in­flat­ed pa­tient cost

Biotech VC firm out­lines plans for $100M fund

No­vo says its CB1 drug helped shed weight, but ef­fi­ca­cy and safe­ty ques­tions re­main

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

FDA OKs the first-ever self-ad­min­is­tered vac­cine, for flu

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times